22 September, 2021

WHO Air Quality Guidelines 2021 – Aiming for healthier air for all

A joint statement by medical, public health, scientific societies and patient representative organisations

After years of intensive research and deliberations with experts across the globe, the World Health Organization (WHO) updated its 2005 Global Air Quality Guidelines (AQG) in September 2021 (WHO 2021; WHO 2017). The new air quality guidelines (WHO AQG) are ambitious and reflect the large impact that air pollution has on global health. They recommend aiming for annual mean concentrations of PM$_{2.5}$ not exceeding 5 μg/m$^3$ and NO$_2$ not exceeding 10 μg/m$^3$, and the peak season mean 8-hr ozone concentration not exceeding 60 μg/m$^3$ (WHO 2021). For reference, the corresponding 2005 WHO guideline values for PM$_{2.5}$ and NO$_2$ were, respectively, 10 μg/m$^3$ and 40 μg/m$^3$ with no recommendation issued for long-term ozone concentrations (WHO 2006). While the guidelines are not legally binding, we hope they will influence air quality policy across the globe for many years to come.

The updated WHO AQG have become so necessary as an overwhelming body of evidence has accumulated over the past two decades, demonstrating that health effects of air pollution are serious and can affect nearly all organ systems of the human body (Thurston et al. 2017). Importantly, recent studies and large research programmes consistently show that the adverse effects of air pollution are not only limited to high exposures; harmful health effects can be observed all the way down to very low concentration levels, with no observable thresholds below which exposure can be considered safe (Brauer et al. 2019; Brunekreef et al. 2021; Dominici et al. 2019).

There is now broad expert consensus that air pollution is a major global public health risk factor and puts an enormous financial burden on societies. Outdoor and household air pollution together accounted for approximately 12% of all deaths in 2019. Air
pollution currently ranks fourth among major risk factors for global disease and mortality, only behind hypertension, smoking and dietary factors (Murray et al. 2020). In terms of economic burden, the estimated global health-related external costs (i.e., those borne by society as a whole) were US$ 5 trillion in 2013 with an additional US$ 225 billion in lost labour productivity (World Bank Group 2016). For the WHO European Region, the overall annual economic cost of health impacts and mortality from air pollution, including estimates for morbidity costs, stood at US$ 1.575 trillion (WHO Regional Office for Europe, OECD 2015).

The most important message of the updated WHO AQG is that each reduction in the outdoor concentrations of key air pollutants brings health benefits to the surrounding population, even in places which already have low pollution concentrations. Moreover, linear exposure-response relationships down to the lowest observable concentrations show that every individual will benefit from cleaner air (Huangfu and Atkinson 2020; Lee et al. 2020; Chen and Hoek 2020; Orellano et al. 2020; Zheng et al. 2021). These findings provide critical input into clean air policies and regulation around the world. They also are key to estimating the potential health and economic benefits from policies that reduce exposure to air pollution.

Recognising that the adverse health effects of pollution exposure can be seen at all, even at the lowest observed levels of pollution concentrations, is a milestone for cleaner air and better health policies. It offers a wake-up call, to reconsider current air quality legislation and regulations. To maximise health benefits, we now understand better the importance of implementing measures to reduce average exposures of all people. Such an approach must complement reductions in exposure at “hotspots” with high levels of air pollution, in particular to address known inequities owing to socioeconomic conditions, increased vulnerability of the residential population, and economic activities (Hooper and Kaufman, 2018). To tackle the health effects of air pollution, bold air quality actions are needed at all levels – international, national, local – and across all sectors such as transport, energy, industry, agriculture and residential.

Most jurisdictions with clean air regulations have relied on fixed limit values with little incentive to further reduce air pollution levels once compliance with the limit value is achieved (Kutlar Joss et al. 2017). Given the evidence that health effects occur all the
way down to very low concentration levels, future clean air policies must include incentives for progressive lowering of exposures of the entire population, thereby improving health for all. What is needed is a paradigm change from relying solely on fixed limit values, with a shift towards the concept of combining fixed limit values with a continuous reduction of the average exposure. For example, the current European Union (EU) Ambient Air Quality Directive already contains a non-binding average exposure reduction target (European Commission 2008). The upcoming 2022 revision of the EU Ambient Air Quality Directive will offer the chance to lead the way and implement binding average exposure reduction goals for air pollutants in combination with lowered fixed limit values.

Programmes that reduce air pollutant emissions provide enormous air quality and health benefits which increase over time. The estimated health benefits of improved air quality outweigh by far the implementation costs of air quality actions. For the US, it has been estimated that the benefits from decreased mortality, lower medical expenditures for air pollution-related diseases, and higher productivity of workers are around 30 times greater than the costs of the Clean Air Act, resulting in net improvements of economic growth, and population welfare (U.S. E.P.A. 2015). In China, public health benefits were 50% greater than the costs for air quality improvement measures (Zhang et al. 2019). Similarly, for the EU, additional clean air and climate policies beyond the current obligations will lead to net benefits with positive macro-economic implications (Amann et al. 2017). Indeed, the cost effectiveness of air quality actions is enhanced by the close link between air pollution and greenhouse gas emissions. A reduction of air pollution emissions will also feed into efforts for climate neutrality and vice versa, making benefits from investments in one area count twice (Amann et al. 2014, IPCC 2021).

Conclusions

Air pollution is a major global public health threat that causes a range of adverse health effects, even at the lowest observable concentrations. There is ample evidence to strongly support government action to reduce air pollution and address climate change simultaneously. The updated WHO AQG are bold and stress the importance of lowering air pollution concentrations at every level. The benefits are clear: lowering air pollution levels will lead to enormous improvements in public health for people of all ages
breathing cleaner air. We support the recommendations of the new WHO AQG, and urge nations to use the WHO AQG as a guide for ambitious air quality and emission reduction policies around the world.

*Signatures of the undersigned organisations:*

Prof. Marc Humbert, President, European Respiratory Society

Mark Nieuwenhuijsen, President, International Society of Environmental Epidemiology

Dr Kjeld Hansen, Chair, European Lung Foundation

Prof. Donald M. Lloyd-Jones, President, American Heart Association

Prof. Lynn Schnapp, President, American Thoracic Society
William G. Cance, MD FACS, Chief Medical and Scientific Officer, American Cancer Society, Inc.

Prof. Tiffany Latrice Gary-Webb, Chair, the American Public Health Association

Prof. John Middleton, President, the Association of Schools of Public Health in the European Region

Dr P.P. Mohanan, President, Cardiological Society of India

Prof. Matti Aapro, President, European Cancer Organisation

Prof. Fausto Pinto, President, World Heart Federation

European Society of Cardiology
Prof. John Upham, President, The Thoracic Society of Australia & New Zealand

Dr Nebojsa Tasic, President, Hypertension, Infarction, and Stroke Prevention Association

Asia-Pacific Society of Respirology

Dr Riccardo Asero, President, the Italian Association of Allergologists and Immunologists

Prof. Federica Zanetto, President, Associazione Culturale Pediatri

Dr Adriano Vaghi, President, Italian Thoracic Society
Prof. Gianenrico Senna, President, Società Italiana Allergologia, Asma ed Immunologia Clinica

Prof. Lucia Bisceglia, President, Italian Association of Epidemiology

Prof. Carla Ancona, President, Italian Network of Environment and Health

Dr Zeina Aoun, President, Lebanese Pulmonary Society

Associate Prof. Dr. Pang Yong Kek, President, Malaysian Thoracic Society

Prof. Luca Richeldi, President, Italian Respiratory Society
Prof. Oya Itil, President, Turkish Thoracic Society

Prof. Paweł Śliwiński, President, Polskie Towarzystwo Chorób Płuc

Prof. Ji Tae Choung, President, Korean Academy of Medical Sciences

Prof. Hae-Kwan Cheong, President; Prof. Sin Kam, Chair of the Board, the Korean Society for Preventive Medicine

Prof. Soon Young Lee, President, Korean Society of Epidemiology
Prof. Jung-Wan Koo, President, Korean Society of Occupational and Environmental Medicine

Prof. Susana I. Garcia, President, Ibero-American Society for Environmental Health

Prof. Mauro Silvestrini, President, Italian Stroke Association

Prof. Fabio Midulla, President, Società Italiana per le Malattie Respiratorie Infantili

Prof. Ülkü Yılmaz, President, Turkish Respiratory Society

Prof. Kamlesh Tewary, President, Association of Physicians of India

Prof. Irma de Godoy, President, Sociedade Brasileira de Pneumonologia e Tisiologia
Prof. Philip J. Landrigan, President, Collegium Ramazzini

Canadian Lung Association

Prof. Annamaria Staiano, President, Società Italiana di Pediatria

Prof. Stylianos Loukides, President, Hellenic Thoracic Society

Dr Jukka Takala, President, International Commission on Occupational Health

Dr Louise M. Perkins, President, Foundation for Sarcoidosis Research
Claudia Spina, President, Associazione Italiana Bronchiettasie

Shane Fitch, President, Lovexair

Alpha 1 Spain

FairLife

Dr Catia Cilloniz Campos, President, the Association for the Support of Patients with Pneumonia and their Families

European Cancer Patient Coalition (ECPC)

Natalia Maeva, President, Bulgarian Society of the patients with PH
Jill Fairweather, Co-founder, Aspergillosis Trust

La Federación Española de Asociaciones de pacientes alérgicos y con Enfermedades Respiratorias (FENAER)

Peter Bruce, Chair, Pulmonary Fibrosis Trust

Delfina Pérez, President, Asociación de Pacientes con EPOC (APEPOC)

Prof. Chantal Raherison, President, SPLF

German Society for Epidemiology

German Society for Public Health

Deutsche Gesellschaft für Kardiologie
Dr Mark A. Ferro, Canadian Society for Epidemiology and Biostatistics

Netherlands Respiratory Society

Steve Jones, President, EU-IPFF

Patiëntenvereniging longtransplantatie UZ Leuven (HALO vzw)

Associazione Nazionale Alfa 1-At ODV

Prof. Dr Christophe von Garnier, President, Swiss Society of Pneumology

Helping Hands Foundation
Healthy Lungs-Nepal

Sarcoidose.nl

LAM Action

Dr Sonali Johnson (PhD), Head, Knowledge, Advocacy and Policy, Union for International Cancer Control (UICC)

Dr Julián Ciruzzi, President, Asociación Argentina de Medicina Respiratoria

Philippine College of Chest Physicians

Sociedad Española de Neumología y Cirugía Torácica (SEPAR)

Prof. Guy Marks, President, International Union Against Tuberculosis and Lung Disease
Anne-Marie Baird

Dr Anne-Marie Baird, President, Lung Cancer Europe

Federasma e Allergie

Taiwan Society of Pulmonary and Critical Care Medicine

APH Macedonia "Moment plus"

Prof. Coenraad Koegelenberg, President, South African Thoracic Society

German Association for Medical Informatics, Biometry and Epidemiology

German Society for Social Medicine and Prevention
Hilde De Keyser, Chief Executive Officer, CF Europe

M.R. Rutgers, Director, Longfonds

Prof. Camille Raynes-Greenow, Chair, International Network for Epidemiology in Policy

Dr Neil Schluger, Co-Founder, Inspire: Health Advocates for Clean Air

Dr Tewodros H. Gebremariam, President, Ethiopian Thoracic Society

Syaogi Ahmed ‘Azizy, President, Center for Indonesian Medical Students’ Activities
Marion Wilkens, 1st Chairperson, Alpha 1 Germany

Carla Jones, President, European Federation of Allergy and Airways Diseases Patients' Associations

Danijela Pesic, President, PHA Europe

Floris Italianer, Director, Dutch Heart Foundation

Gesellschaft für Pädiatrische Pneumologie

Kristina Sparreljung, Secretary General, the Swedish Heart-Lung Foundation
Sarcoidosis UK

Sarah Woolnough, Chief Executive, Asthma UK/British Lung Foundation

Eva Garcia, President, Asociación Nacional de Hipertensión Pulmonar

Breathe Easy

European Chronic Disease Alliance

Dr Milka Sokolovic, Director-General, European Public Health Alliance

Prof. Dr Marc Saez, Main Researcher, Research Group on Statistics, Econometrics and Health (GRECS), University of Girona, Spain and CIBER of Epidemiology and Public Health (CIBERESP)
Alpha 1 Belgium

American Lung Association

Associazione Nazionale Alfa 1

Belgian Respiratory Society

European Alliance of Associations for Rheumatology

Korean Academy of Tuberculosis and Respiratory Diseases

Stichting Huize Aarde

Swedish Asthma and Allergy Association

European Chronic Disease Alliance

Association for Respiratory Technology & Physiology (ARTP)
Members of the writing group: Barbara Hoffmann, Hanna Boogaard, Audrey de Nazelle, Zorana J. Andersen, Michael Abramson, Michael Brauer, Bert Brunekreef, Francesco Forastiere, Wei Huang, Haidong Kan, Joel Kaufman, Klea Katsouyanni, Michal Krzyzanowski, Nino Künzli, Francine Laden, Mark Nieuwenhuijsen, Adetoun Mustapha, Pippa Powell, Mary Rice, Aina Roca-Barceló, Charlotte Roscoe, Agnes Soares, Kurt Straif, George Thurston

Publication bibliography


Brauer, Michael; Brook, Jeffrey R.; Christidis, Tanya; Chu, Yen; Crouse, Dan L.; Erickson, Anders et al. (2019): Mortality–Air Pollution Associations in Low-


Dominici, Francesca; Schwartz, Joel; Di, Qian; Braun, Danielle; Choirat, Christine; Zanobetti, Antonella (2019): Assessing Adverse Health Effects of Long-Term Exposure to Low Levels of Ambient Air Pollution: Phase 1. In Research Reports: Health Effects Institute 2019.


Lee, Kuan Ken; Spath, Nicholas; Miller, Mark R.; Mills, Nicholas L.; Shah, Anoop S. V. (2020): Short-term exposure to carbon monoxide and myocardial infarction:


Orellano, Pablo; Reynoso, Julieta; Quaranta, Nancy; Bardach, Ariel; Ciapponi, Agustin (2020): Short-term exposure to particulate matter (PM10 and PM2.5), nitrogen dioxide (NO2), and ozone (O3) and all-cause and cause-specific mortality: Systematic review and meta-analysis. In *Environment International* 142, p. 105876. DOI: 10.1016/j.envint.2020.105876.


WHO Regional Office for Europe, OECD (2015): Economic cost of the health impact of air pollution in Europe: Clean air, health and wealth. Edited by WHO Regional Office for Europe, Copenhagen, Denmark.


